Name | 3-Amino-1-propanesulfonic acid |
Synonyms | 3 APS HOMOTAURINE Homotaurine TRAMIPROSATE 3-AMINOPROPANESULFONIC ACID 3-Amino-1-propanesulfonic acid 3-AMINOPROPANE-1-SULFONIC ACID 3-AMINO-1-PROPANESULFONIC ACID 3-aminopropane-1-sulphonic acid aminopropanesulfonicacid,3-aminopropanesulfonicacid |
CAS | 3687-18-1 |
EINECS | 222-977-4 |
InChI | InChI=1/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7) |
Molecular Formula | C3H9NO3S |
Molar Mass | 139.17 |
Density | 1.202 (estimate) |
Melting Point | 293°C (dec.)(lit.) |
Solubility | Water (Slightly) |
Appearance | Crystalline Powder |
Color | White to slightly blue |
pKa | 1.06±0.50(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.5130 (estimate) |
MDL | MFCD00008225 |
Use | As an intermediate of acamprosate, a therapeutic agent for alcoholism |
In vitro study | Tramiprosate (200 μg/mL, 40 μg/mL, 8 μg/mL and 1.6 μg/mL; 1 hours) significantly attenuates oxygen/glucose deprivation (OGD)- or NMDA-induced injury in NGF-differentiated PC12 cells and primary cortical neurons. Tramiprosate decreases the intensity of the association between nNOS and PSD95, and Tramiprosate also inhibits the translocation of nNOS from the cytosol to the membrane. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 1 |
HS Code | 29049090 |
LogP | -4.555 |
Overview | 3-aminopropane sulfonic acid is a promising candidate for the treatment of AD. Currently in phase III clinical trials in North America and Europe. Clinical trial results have been published. 3-aminopropane sulfonic acid is recognized as capable of reducing the aggregation, deposition and/or loading of amyloid in the brain through its binding action to soluble Aβ peptides. |
Application | This metabolic process of 3-aminopropane sulfonic acid has a significant effect on its pharmacokinetic profile and its drug efficacy. In order to improve the therapeutic effect of 3-aminopropane sulfonic acid and increase its overall bioavailability, such as improving stability or slowing down metabolism, an effective way is to make a prodrug or derivative of 3-aminopropane sulfonic acid, so that it can produce 3-aminopropane sulfonic acid in the body of the subject after administration. |
biological activity | Tramiprosate (Homotaurine), a natural amino acid with oral activity and permeability to the blood-brain barrier, exists in various red seaweeds. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog with neuroprotective, anticonvulsant and antihypertensive effects. |
Target | Value |
Animal Model: | Adult male Sprague-Dawley rats (200-250 g) subjected to middle cerebral artery occlusion (MCAO) |
Dosage: | 50 mg/kg, 25 mg/kg, 12.5 mg/kg or 6.25 mg/kg |
Administration: | Intraperitoneal injection; once |
Result: | Dose-dependently reduced the infarct volume after MCAO. |
Use | Used as an intermediate for acammatic acid as a therapeutic agent for alcoholism |